Ravi S Hira1, Sreekanth Vemulapalli2, Zhuokai Li2, James M McCabe1, John S Rumsfeld3, Samir R Kapadia4, Mahboob Alam5, Hani Jneid5,6, Creighton Don1, Mark Reisman1, Salim S Virani5,6,7, Neal S Kleiman7,8. 1. Section of Cardiology, University of Washington, Seattle. 2. Duke Clinical Research Institute, Durham, North Carolina. 3. University of Colorado School of Medicine, Aurora. 4. Cleveland Clinic, Cleveland, Ohio. 5. Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas. 6. Baylor College of Medicine, Houston, Texas. 7. Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas. 8. Weill Cornell Medical College, New York, New York.
Abstract
Importance: Transcatheter aortic valve replacement (TAVR) was approved by the US Food and Drug Administration for severe aortic stenosis in patients who cannot undergo surgery and for patients at high operative risk. Use of TAVR for off-label indications has not been previously reported. Objective: To evaluate patterns and adverse outcomes of off-label use of TAVR in US clinical practice. Design, Setting and Participants: Patients receiving commercially funded TAVR in the United States are included in the Transcatheter Valve Therapy Registry. A total of 23 847 patients from 328 sites performing TAVR between November 9, 2011, and September 30, 2014, were assessed for this study. Off-label TAVR was defined as TAVR in patients with known bicuspid valve, moderate aortic stenosis, severe mitral regurgitation, severe aortic regurgitation, or subaortic stenosis. Data were linked with the Centers for Medicare & Medicaid Services for 15 397 patients to evaluate 30-day and 1-year outcomes. Exposure: Off-label use of TAVR. Main Outcomes and Measures: Frequency of off-label TAVR use and the association with in-hospital, 30-day, and 1-year adverse outcomes. Results: Among the 23 847 patients in the study (11 876 women and 11 971 men; median age, 84 years [interquartile range, 78-88 years]), off-label TAVR was used in 2272 patients (9.5%). In-hospital mortality was higher among patients receiving off-label TAVR than those receiving on-label TAVR (6.3% vs 4.7%; P < .001), as was 30-day mortality (8.5% vs 6.1%; P < .001) and 1-year mortality (25.6% vs 22.1%; P = .001). Adjusted 30-day mortality was higher in the off-label group (hazard ratio, 1.27; 95% CI, 1.04-1.55; P = .02), while adjusted 1-year mortality was similar in the 2 groups (hazard ratio, 1.11; 95% CI, 0.98-1.25; P = .11). The median rate of off-label TAVR use per hospital was 6.8% (range, 0%-34.7%; interquartile range, 3.4%-12.1%), with hospitals in the highest tertile of off-label use associated with increased 30-day adverse cardiovascular events compared with the lowest tertile. However, this difference was not observed in adjusted 30-day or 1-year outcomes. Conclusions and Relevance: Approximately 1 in 10 patients in the United States have received TAVR for an off-label indication. After adjustment, 1-year mortality was similar in these patients to that in patients who received TAVR for an on-label indication. These results reinforce the need for additional research on the efficacy of off-label TAVR use.
Importance: Transcatheter aortic valve replacement (TAVR) was approved by the US Food and Drug Administration for severe aortic stenosis in patients who cannot undergo surgery and for patients at high operative risk. Use of TAVR for off-label indications has not been previously reported. Objective: To evaluate patterns and adverse outcomes of off-label use of TAVR in US clinical practice. Design, Setting and Participants: Patients receiving commercially funded TAVR in the United States are included in the Transcatheter Valve Therapy Registry. A total of 23 847 patients from 328 sites performing TAVR between November 9, 2011, and September 30, 2014, were assessed for this study. Off-label TAVR was defined as TAVR in patients with known bicuspid valve, moderate aortic stenosis, severe mitral regurgitation, severe aortic regurgitation, or subaortic stenosis. Data were linked with the Centers for Medicare & Medicaid Services for 15 397 patients to evaluate 30-day and 1-year outcomes. Exposure: Off-label use of TAVR. Main Outcomes and Measures: Frequency of off-label TAVR use and the association with in-hospital, 30-day, and 1-year adverse outcomes. Results: Among the 23 847 patients in the study (11 876 women and 11 971 men; median age, 84 years [interquartile range, 78-88 years]), off-label TAVR was used in 2272 patients (9.5%). In-hospital mortality was higher among patients receiving off-label TAVR than those receiving on-label TAVR (6.3% vs 4.7%; P < .001), as was 30-day mortality (8.5% vs 6.1%; P < .001) and 1-year mortality (25.6% vs 22.1%; P = .001). Adjusted 30-day mortality was higher in the off-label group (hazard ratio, 1.27; 95% CI, 1.04-1.55; P = .02), while adjusted 1-year mortality was similar in the 2 groups (hazard ratio, 1.11; 95% CI, 0.98-1.25; P = .11). The median rate of off-label TAVR use per hospital was 6.8% (range, 0%-34.7%; interquartile range, 3.4%-12.1%), with hospitals in the highest tertile of off-label use associated with increased 30-day adverse cardiovascular events compared with the lowest tertile. However, this difference was not observed in adjusted 30-day or 1-year outcomes. Conclusions and Relevance: Approximately 1 in 10 patients in the United States have received TAVR for an off-label indication. After adjustment, 1-year mortality was similar in these patients to that in patients who received TAVR for an on-label indication. These results reinforce the need for additional research on the efficacy of off-label TAVR use.
Authors: Martin B Leon; Craig R Smith; Michael Mack; D Craig Miller; Jeffrey W Moses; Lars G Svensson; E Murat Tuzcu; John G Webb; Gregory P Fontana; Raj R Makkar; David L Brown; Peter C Block; Robert A Guyton; Augusto D Pichard; Joseph E Bavaria; Howard C Herrmann; Pamela S Douglas; John L Petersen; Jodi J Akin; William N Anderson; Duolao Wang; Stuart Pocock Journal: N Engl J Med Date: 2010-09-22 Impact factor: 91.245
Authors: Sunil V Rao; Richard E Shaw; Ralph G Brindis; Lloyd W Klein; William S Weintraub; Eric D Peterson Journal: Am J Cardiol Date: 2006-03-29 Impact factor: 2.778
Authors: Craig R Smith; Martin B Leon; Michael J Mack; D Craig Miller; Jeffrey W Moses; Lars G Svensson; E Murat Tuzcu; John G Webb; Gregory P Fontana; Raj R Makkar; Mathew Williams; Todd Dewey; Samir Kapadia; Vasilis Babaliaros; Vinod H Thourani; Paul Corso; Augusto D Pichard; Joseph E Bavaria; Howard C Herrmann; Jodi J Akin; William N Anderson; Duolao Wang; Stuart J Pocock Journal: N Engl J Med Date: 2011-06-05 Impact factor: 91.245
Authors: David A Roy; Ulrich Schaefer; Victor Guetta; David Hildick-Smith; Helge Möllmann; Nicholas Dumonteil; Thomas Modine; Johan Bosmans; Anna Sonia Petronio; Neil Moat; Axel Linke; Cesar Moris; Didier Champagnac; Radoslaw Parma; Andrzej Ochala; Diego Medvedofsky; Tiffany Patterson; Felix Woitek; Marjan Jahangiri; Jean-Claude Laborde; Stephen J Brecker Journal: J Am Coll Cardiol Date: 2013-02-20 Impact factor: 24.094
Authors: John D Carroll; Fred H Edwards; Danica Marinac-Dabic; Ralph G Brindis; Frederick L Grover; Eric D Peterson; E Murat Tuzcu; David M Shahian; John S Rumsfeld; Cynthia M Shewan; Kathleen Hewitt; David R Holmes; Michael J Mack Journal: J Am Coll Cardiol Date: 2013-05-01 Impact factor: 24.094
Authors: David H Adams; Jeffrey J Popma; Michael J Reardon; Steven J Yakubov; Joseph S Coselli; G Michael Deeb; Thomas G Gleason; Maurice Buchbinder; James Hermiller; Neal S Kleiman; Stan Chetcuti; John Heiser; William Merhi; George Zorn; Peter Tadros; Newell Robinson; George Petrossian; G Chad Hughes; J Kevin Harrison; John Conte; Brijeshwar Maini; Mubashir Mumtaz; Sharla Chenoweth; Jae K Oh Journal: N Engl J Med Date: 2014-03-29 Impact factor: 91.245
Authors: Darren Mylotte; Thierry Lefevre; Lars Søndergaard; Yusuke Watanabe; Thomas Modine; Danny Dvir; Johan Bosmans; Didier Tchetche; Ran Kornowski; Jan-Malte Sinning; Pascal Thériault-Lauzier; Crochan J O'Sullivan; Marco Barbanti; Nicolas Debry; Jean Buithieu; Pablo Codner; Magdalena Dorfmeister; Giuseppe Martucci; Georg Nickenig; Peter Wenaweser; Corrado Tamburino; Eberhard Grube; John G Webb; Stephan Windecker; Ruediger Lange; Nicolo Piazza Journal: J Am Coll Cardiol Date: 2014-12-01 Impact factor: 24.094
Authors: A Pieter Kappetein; Stuart J Head; Philippe Généreux; Nicolo Piazza; Nicolas M van Mieghem; Eugene H Blackstone; Thomas G Brott; David J Cohen; Donald E Cutlip; Gerrit-Anne van Es; Rebecca T Hahn; Ajay J Kirtane; Mitchell W Krucoff; Susheel Kodali; Michael J Mack; Roxana Mehran; Josep Rodés-Cabau; Pascal Vranckx; John G Webb; Stephan Windecker; Patrick W Serruys; Martin B Leon Journal: J Am Coll Cardiol Date: 2012-10-09 Impact factor: 24.094
Authors: Danny Dvir; John G Webb; Sabine Bleiziffer; Miralem Pasic; Ron Waksman; Susheel Kodali; Marco Barbanti; Azeem Latib; Ulrich Schaefer; Josep Rodés-Cabau; Hendrik Treede; Nicolo Piazza; David Hildick-Smith; Dominique Himbert; Thomas Walther; Christian Hengstenberg; Henrik Nissen; Raffi Bekeredjian; Patrizia Presbitero; Enrico Ferrari; Amit Segev; Arend de Weger; Stephan Windecker; Neil E Moat; Massimo Napodano; Manuel Wilbring; Alfredo G Cerillo; Stephen Brecker; Didier Tchetche; Thierry Lefèvre; Federico De Marco; Claudia Fiorina; Anna Sonia Petronio; Rui C Teles; Luca Testa; Jean-Claude Laborde; Martin B Leon; Ran Kornowski Journal: JAMA Date: 2014-07 Impact factor: 56.272
Authors: Michael J Mack; J Matthew Brennan; Ralph Brindis; John Carroll; Fred Edwards; Fred Grover; David Shahian; E Murat Tuzcu; Eric D Peterson; John S Rumsfeld; Kathleen Hewitt; Cynthia Shewan; Joan Michaels; Barb Christensen; Alexander Christian; Sean O'Brien; David Holmes Journal: JAMA Date: 2013-11-20 Impact factor: 56.272
Authors: Peter E Umukoro; Paul Yeung-Lai-Wah; Sunil Pathak; Sabri Elkhidir; Deepa Soodi; Brooke Delgoffe; Richard Berg; Kelley P Anderson; Romel J Garcia-Montilla Journal: Clin Med Res Date: 2020-10-14
Authors: Raj R Makkar; Sung-Han Yoon; Martin B Leon; Tarun Chakravarty; Michael Rinaldi; Pinak B Shah; Eric R Skipper; Vinod H Thourani; Vasilis Babaliaros; Wen Cheng; Alfredo Trento; Sreekanth Vemulapalli; Samir R Kapadia; Susheel Kodali; Michael J Mack; Gilbert H L Tang; Tsuyoshi Kaneko Journal: JAMA Date: 2019-06-11 Impact factor: 56.272
Authors: Tamunoinemi Bob-Manuel; Arindam Sharma; Amit Nanda; Devarshi Ardeshna; William Paul Skelton; Rami N Khouzam Journal: Ann Transl Med Date: 2018-01
Authors: Matthew A Jolley; Andras Lasso; Hannah H Nam; Patrick V Dinh; Adam B Scanlan; Alex V Nguyen; Anna Ilina; Brian Morray; Andrew C Glatz; Francis X McGowan; Kevin Whitehead; Yoav Dori; Joseph H Gorman; Robert C Gorman; Gabor Fichtinger; Matthew J Gillespie Journal: Catheter Cardiovasc Interv Date: 2018-11-15 Impact factor: 2.692
Authors: Tian-Yuan Xiong; Walid Ben Ali; Yuan Feng; Kentaro Hayashida; Hasan Jilaihawi; Azeem Latib; Michael Kang-Yin Lee; Martin B Leon; Raj R Makkar; Thomas Modine; Christoph Naber; Yong Peng; Nicolo Piazza; Michael J Reardon; Simon Redwood; Ashok Seth; Lars Sondergaard; Edgar Tay; Didier Tchetche; Wei-Hsian Yin; Mao Chen; Bernard Prendergast; Darren Mylotte Journal: Nat Rev Cardiol Date: 2022-06-20 Impact factor: 32.419
Authors: Prashant V Rajan; Jessica N Holtzman; Aaron S Kesselheim; Robert W Yeh; Daniel B Kramer Journal: J Am Heart Assoc Date: 2019-06-01 Impact factor: 5.501